CapsoVision, Inc. (NASDAQ: CV) saw its shares soar 6.90% during intraday trading on Wednesday, marking a strong debut for the medical technology company following its initial public offering (IPO). The impressive start comes after CapsoVision priced its IPO at $5 per share, aiming to raise approximately $27.5 million in gross proceeds.

The company offered 5.5 million shares to the public, with trading commencing on the Nasdaq under the ticker symbol "CV". The enthusiastic market reception suggests investors are optimistic about CapsoVision's prospects in the medical technology sector. The IPO is expected to close on Thursday, solidifying the company's position in the public market.

Adding to the positive sentiment, CapsoVision has granted its underwriters a 30-day option to purchase up to an additional 825,000 shares. This overallotment provision could potentially increase the total funds raised if exercised. As the medical technology landscape continues to evolve, investors appear eager to support innovative companies like CapsoVision, as evidenced by the strong first-day performance of its stock.